Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension

Mancusi, Costantino; Borghi, Claudio; Ferri, Claudio; Muiesan, María Lorenza; Volpe, Massimo; Iaccarino, Guido

doi:10.1007/s40292-020-00429-3

Cited by 23 publications

(22 citation statements)

References 33 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, ischemic heart disease and chronic obstructive pulmonary disease did increase the risk of complications requiring ICU admission, consistent with what was found by other authors [27][28][29]. Likewise, the probability of dying increased 16% for each 1-point increase in the Charlson comorbidity index, a finding similar to that documented in a group of patients in Spain (OR:1.23; 95%CI:1.15-1.32) [28] and in a cohort of patients in the USA; in those cohorts, mortality increased from 40 to 93% depending the scoring method [19], making it a useful tool to identify patients with a higher risk of mortality and therefore those who require closer clinical monitoring [30].…”

Section: Plos Onesupporting

confidence: 74%

Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia

et al. 2021

View full text Add to dashboard Cite

Introduction Coronavirus disease 2019 (COVID-19) has affected millions of people worldwide, and several sociodemographic variables, comorbidities and care variables have been associated with complications and mortality. Objective To identify the factors associated with admission to intensive care units (ICUs) and mortality in patients with COVID-19 from 4 clinics in Colombia. Methods This was a follow-up study of a cohort of patients diagnosed with COVID-19 between March and August 2020. Sociodemographic, clinical (Charlson comorbidity index and NEWS 2 score) and pharmacological variables were identified. Multivariate analyses were performed to identify variables associated with the risk of admission to the ICU and death (p<0.05). Results A total of 780 patients were analyzed, with a median age of 57.0 years; 61.2% were male. On admission, 54.9% were classified as severely ill, 65.3% were diagnosed with acute respiratory distress syndrome, 32.4% were admitted to the ICU, and 26.0% died. The factors associated with a greater likelihood of ICU admission were severe pneumonia (OR: 9.86; 95%CI:5.99–16.23), each 1-point increase in the NEWS 2 score (OR:1.09; 95%CI:1.002–1.19), history of ischemic heart disease (OR:3.24; 95%CI:1.16–9.00), and chronic obstructive pulmonary disease (OR:2.07; 95%CI:1.09–3.90). The risk of dying increased in those older than 65 years (OR:3.08; 95%CI:1.66–5.71), in patients with acute renal failure (OR:6.96; 95%CI:4.41–11.78), admitted to the ICU (OR:6.31; 95%CI:3.63–10.95), and for each 1-point increase in the Charlson comorbidity index (OR:1.16; 95%CI:1.002–1.35). Conclusions Factors related to increasing the probability of requiring ICU care or dying in patients with COVID-19 were identified, facilitating the development of anticipatory intervention measures that favor comprehensive care and improve patient prognosis.

show abstract

Section: Plos Onesupporting

confidence: 74%

Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Severe to critical COVID-19 encompasses respiratory failure, septic shock, and/or multiple organ dysfunction/failure; of note, immune mechanisms are critically involved in evolution of severe COVID-19, suggesting potential efficacy of immunomodulatory treatments [ 2 ]. The mortality rate varies according to age being less than 5% up to the 6th decade, and progressively increases by each single year of age in people aged 60 or above [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

Pericarditis after SARS-CoV-2 Infection: Another Pebble in the Mosaic of Long COVID?

Carubbi

Alunno

Leone

et al. 2021

Viruses

Self Cite

View full text Add to dashboard Cite

With the emerging success of the COVID-19 vaccination programs, the incidence of acute COVID-19 will decrease. However, given the high number of people who contracted SARS-CoV-2 infection and recovered, we will be faced with a significant number of patients with persistent symptoms even months after their COVID-19 infection. In this setting, long COVID and its cardiovascular manifestations, including pericarditis, need to become a top priority for healthcare systems as a new chronic disease process. Concerning the relationship between COVID-19 and pericardial diseases, pericarditis appears to be common in the acute infection but rare in the postacute period, while small pericardial effusions may be relatively common in the postacute period of COVID-19. Here, we reported a series of 7 patients developing pericarditis after a median of 20 days from clinical and virological recovery from SARS-CoV-2 infection. We excluded specific identifiable causes of pericarditis, hence we speculate that these cases can be contextualized within the clinical spectrum of long COVID . All our patients were treated with a combination of colchicine and either ASA or NSAIDs, but four of them did not achieve a clinical response. When switched to glucocorticoids, these four patients recovered with no recurrence during drug tapering. Based on this observation and on the latency of pericarditis occurrence (a median of 20 days after a negative nasopharyngeal swab), could be suggested that post-COVID pericarditis may be linked to ongoing inflammation sustained by the persistence of viral nucleic acid without virus replication in the pericardium. Therefore, glucocorticoids may be a suitable treatment option in patients not responding or intolerant to conventional therapy and who require to counteract the pericardial inflammatory component rather than direct an acute viral injury to the pericardial tissue.

show abstract

“…Among this, also the Cardio-Vascular (CV) system can be severely damaged [ 2 ]. It is now clear that both patients with classic CV risk factors (diabetes mellitus, arterial hypertension, obesity) and patients with established CV disease represent a vulnerable population in terms of greater morbidity and mortality [ 3 ]. However this topic have been extensively studied and reviewed and its discussion is beyond the purpose of the present paper.…”

Section: Introductionmentioning

confidence: 99%

Covid and Cardiovascular Diseases: Direct and Indirect Damages and Future Perspective

Ruzzenenti

Maloberti

Giani

et al. 2021

High Blood Press Cardiovasc Prev

View full text Add to dashboard Cite

SARS-CoV-2 infection determines a disease that predominantly affects lungs. However the cytokines storms, determined by the huge immune response to the infection, could affect also other organs and apparatus such as heart and vessels. Beyond the acute inflammation itself also hypercoagulative status has been linked to SARSCoV-2 infection and this surely relates to the increase seen in prevalence of pulmonary embolism and myocardial infarction. A number of cardiac abnormalities and pathologies have been observed, with special attention to cardiac arrhythmias and myocardial involvement. Furthermore, indirect damages determined by the reduction in acute and chronic cardiovascular care, results in a strong mortality and morbidity outcomes in cardiological patients. In this review we will summarise current knowledge on both direct and indirect cardiovascular damages determined by the SARS-CoV-2 pandemia.

show abstract

Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension

Cited by 23 publications

References 33 publications

Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia

Factors associated with admission to the intensive care unit and mortality in patients with COVID-19, Colombia

Pericarditis after SARS-CoV-2 Infection: Another Pebble in the Mosaic of Long COVID?

Covid and Cardiovascular Diseases: Direct and Indirect Damages and Future Perspective

Contact Info

Product

Resources

About